To compare Pulmonary function test at base line (on conventional medical treatment) and after 6 weeks of home based pulmonary rehabilitation program

Abstract

Background &Method: This study was conducted at GMC, Bhopal with aim to compare Pulmonary function test at base line (on conventional medical treatment) and after 6 weeks of home based pulmonary rehabilitation program. This consisted of inhaled salbutamol (100-200g 04-06 times per day) and inhaled ipratropium bromide 02 inhalations 03-04 times per day. Patients were also advised to take additional inhalations of salbutamol as and when they felt the need. Result: The 6 MWD increased from 380.30±22.9 at the first baseline evaluation to 406.92±95.62 at the time of second evolution. These changes were statistically significant. The VAS rating decreased from 30±16.31 at the first baseline evaluation to 20±13.82 at the time of second evaluation. This change was statistically significant. FVCex changed increased from 2.3±0.92 to 2.3±0.9 at the time of the second evaluation after 6 weeks of the exercise training program. This change was not statistically significant. The FVCex % increased from 67.92±12.25 at the first baseline evaluation to 70.41±5.36 at the time of second evaluation after 6 weeks of exercise training program. This change was statistically significant. FEVI increased from 1.890±0.87 to 1.97±0.61 at the time of the second evaluation after 6 weeks of the exercise training program. This change was statistically significant. The FEVI % decreased from 68.04±16.32 at the first baseline evaluation to 70.86± 19.18 at the time of second evaluation. This change was statistically significant. The FEV1/ FVCex decreased from 0.86 ± 0.09to 0.85 ± 0.6 at second evaluation. The change was not significant statistically. Conclusion: A six week home based pulmonary rehabilitation program consisting of exercise training and patient education was effective significantly in increasing exercise endurance and reducing the severity of dyspnoea and improving the quality of life in patients with stable COPD and bronchial asthma.